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Early protocol renal allograft biopsies and graft outcome. To evaluate
whether biopsies performed early after transplantation in stable grafts can
predict graft failure due to chronic transplant nephropathy, a protocol
biopsy was performed at three months in 98 patients treated with
antilymphocytic antibodies, cyclosporine and prednisone. Patients were
followed for 58 16 months. Histological diagnosis according to the Banif
schema were: normal (N = 41), borderline changes (N = 12), chronic
transplant nephropathy (CTN; N = 30), CTN associated to borderline
changes (N = 11) and acute rejection (N = 4). Biopsies displaying acute
rejection were not considered for statistical analysis. Since clinical char-
acteristics of patients with normal histology and borderline changes, as
well as characteristics of patients displaying CTN either with or without
tubulitis were not different, biopsies were grouped as presence or absence
of CTN. Patients displaying CTN had an increased incidence of acute
rejection before performing biopsy (24.3 vs. 3.9%, P = 0.003), a higher
mean cyclosporine level until biopsy (242 74 vs. 214 59 ng/ml, P =
0.049) and a lower actuarial graft survival (80.5% vs. 94.4%, P = 0.024).
We conclude that early protocol biopsies are useful to detect patients at
risk of losing their graft due to chronic transplant nephropathy.
The incidence of acute rejection and consequently, the propor-
tion of grafts lost during the first year after transplantation have
decreased since the introduction of cyclosporine [1]. However, the
rate of grafts lost after the first year remains unchanged [21.
Chronic transplant nephropathy is the most common cause of late
graft failure [31. The possibility of graft failure is suspected by a
sustained and irreversible decline of renal function usually in
conjunction with proteinuria and hypertension [4]. Unfortunately,
once the clinical diagnosis is histologically confirmed, the degree
of renal scarring is usually too advanced to try any potentially
effective therapy [51.
The Banif classification of kidney transplant pathology [6, 7] has
contributed to international uniformity in the evaluation of renal
allograft biopsies. However, limited information is available on
the clinical implications of this classification system. This is
especially true in the case of protocol biopsies which can display
variable degrees of acute and chronic renal lesions [8—12]. There-
fore, the aim of the present work was to characterize renal
damage in biopsies performed in stable renal allografts early after
transplantation according to the Banif schema, and to evaluate
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whether these lesions may help to predict graft loss due to chronic
transplant nephropathy.
Methods
Patients
Between June 1988 and December 1992, a total of 289 patients
received a cadaveric renal transplant in our center. A protocol
renal allograft biopsy was performed in stable grafts between the
second and the fifth months of follow-up if they fulfilled the
following inclusion criteria: (a) serum creatinine lower than 200
j.mol/liter at the time of biopsy; (b) variability of serum creatinine
of less than 15% during two weeks before and after biopsy; (c)
proteinuria lower than 1 g/24 hours. Patients who suffered from
post-transplant acute tubular necrosis and patients who presented
an episode of acute rejection before performing the protocol
biopsy were included if they fulfilled the inclusion criteria.
Since the aim of the study was to evaluate whether there is a
relationship between biopsy findings in stable grafts and graft
failure due to biopsy-proven chronic transplant nephropathy,
patients who experienced an episode of acute rejection after
biopsy and patients who lost their graft due to any reason other
than chronic transplant nephropathy were excluded.
In all patients with a sustained decline of renal function a biopsy
was performed to investigate the cause of late graft failure.
Definition of clinical variables
The following variables were evaluated in each patient at the
time of surgery: age and sex of the recipient, peak and last panel
reactivity antibodies, number of HLA mismatches, donor age,
cold ischemia time (CIT) and immunosuppressive treatment.
After surgery, the following variables were evaluated: time of
biopsy, body wt, post-transplant acute tubular necrosis, acute
rejection, proteinuria and serum creatinine at the time of biopsy,
evolution of serum creatinine during follow-up, mean cyclospo-
rifle dose and mean cyclosporine level between surgery and renal
biopsy, and graft loss due to biopsy-proven chronic transplant
nephropathy.
The immunosuppressive treatment used in our center has been
previously described [13]. Briefly, patients received either antilym-
phocytic globulin (ALG) or OKT3 as induction therapy and
cyclosporine (C5A) and prednisone as maintenance treatment.
ALG was given at a dose of 15 mg/kg just before surgery, 12 mg/kg
the first day after transplant, followed by four doses of 10 mg/kg
on alternate days. OKT3 was given at a dose of 5 mg just before
SerOn et al: Early protocol renal allograft biopsies 311
transplant, followed by four daily doses of 5 mg. Cyclosporine was
started at 3 mg/kg iv. before surgery and continued at 1 mg/kg/12
hours i.v. postoperatively until the oral route could be started at 8
mg/kg/day. Dose modifications were done according to CsA whole
blood levels (RIA, monoclonal). Prednisone was started at 0.25
mg/kg/day and was gradually tapered to 0.1 mg/kg/day in two to
three months.
Post-transplant acute tubular necrosis was defined as hemodi-
alysis requirements after surgery once hyperacute or accelerated
rejection, vascular complications and urinary tract obstruction
were ruled out.
The diagnosis of acute rejection was based on classical clinical
data and in most instances histological criteria. Rejection episodes
were treated with three boluses of 500 mg of methyiprednisolone.
In this group of patients there were no episodes of steroid-
resistant acute rejection.
The mean cyclosporine dose received until biopsy was calcu-
lated from the cyclosporine dose at days 1, 7, 14, 30, 60, 90 and the
day of biopsy. The mean cyclosporine level was calculated from
cyclosporine levels at the same periods of time.
Biopsies
Biopsies were performed with a standard 14 gauge Tru-cut
needle (Travenol, Deerfield, IL, USA) until May 1990. At this
time, the protocol was stopped since a patient presented an
episode of hematuria with ureteral obstruction that was success-
fully treated. On February 1991 the protocol was restarted using
a spring-loaded 18 gauge needle (C.R. Bard Inc., Covington, GA,
USA) under ultrasound guidance. Apart from three episodes of
minor hematuria, no other complications were seen.
Two cores of tissue were obtained in each case; one was
processed for routine histology and the other was snap frozen
until use.
Optical microscopy. Biopsies were formalin fixed, embedded in
paraffin, serially sectioned at approximatelly 4 Jim thick and
stained with hematoxylin-eosin, periodic acid-Schiff (PAS), Mas-
son's trichrome and silver methenamine.
Biopsies that did not contain glomeruli or at least one artery
were not considered. Renal lesions were evaluated and diagnosed
according to the Banif schema [6, 71 by two observers in the
absence of any clinical information. Protocol biopsies were not
available to clinicians and consequently were not employed to
make any clinical decision.
Moiphoinetiy. Cortical interstitial volume fraction (Vvint/cor-
tex) was measured with a point counting technique at x400
magnification on silver methenamine stained sections as previ-
ously described [14].
Number of infiltrating leukocytes. Frozen sections were stained
using the avidin biotin method with a monoclonal antibody
directed against common leukocytc antigen CD45 (PD7/26; Dako,
Denmark). The number of positively stained cells was counted at
x400 magnification and the result was expressed as the number of
infiltrating cells/mm2 of cortical interstitium as previously de-
scribed [151.
Statistics
Results were expressed as the mean SD.
In the first statistical approach, analysis of variance was em-
ployed to compare quantitative data in the different diagnostic
categories and the Scheffé test was used for individual compari-
sons. The Kruskall-Wallis and Chi-square tests were applied for
ordinal and categorical data, respectively.
The result of this first analysis suggested to group patients in
two new diagnostic categories: presence or absence of CTN.
Clinical data in these two new categories were compared either
with Student's t-test, the Mann-Whitney U-test or 2 X 2 contin-
gency tables.
To further analyze independent predictors of CTN, a logistic-
regression model was applied [16].
Kaplan-Meier analysis was used to calculate actuarial graft
survival and the log-rank test was employed to compare survival
between groups. In order to study the independent predictors of
graft survival, data were further analyzed by means of Cox's
proportional hazard model.
For factors with only two categories, logistic-regression and
Cox's proportional hazard model were used to calculate the
relative risk estimate. For continuous factors, the relative risk
estimate per unit of measurement was calculated [17]. Indepen-
dent variables were checked for co-linearity.
All P values were two tailed and a P value < 0.05 was
considered significant.
Results
Patients
One hundred twenty-six patients gave their consent to partici-
pate in this study. In 4 cases cortical tissue was not obtained and
in 17 cases only one core of frozen tissue was available. These 21
cases were not included in the study. Seven more patients were
excluded for the following reasons: death with a functioning graft
(N = 2), graft loss due to membranoproliferative glomerulone-
phritis associated to cryoglobulinemia and hepatitis C virus infec-
tion (N = 2), acute rejection after the protocol biopsy (N 2) and
non-treatment compliance (N = 1).
Finally, 98 patients were included: 58 males and 40 females of
a mean age of 41 13 years. Eighty-nine patients received a first
and 9 a second cadaveric renal transplant. Fifty-one were treated
with ALG as the induction therapy and 47 with OKT3. Twelve
patients were treated for an acute rejection episode 75 34 days
before the protocol biopsy. Mean follow-up was 58 16 months
(range 25 to 85) and during this period of time 11 patients lost
their graft at 38 9 months (range 25 to 51 months). In these 11
patients urinary tract obstruction, chronic urinary tract infection
and renal transplant artery stenosis were ruled out. A diagnostic
renal biopsy was performed in all cases. In 7 cases at least one
artery showed myointimal proliferation, and consequently they
were diagnosed with chronic rejection. In the other 4 patients the
renal arteries did not show myointimal proliferation. They were
diagnosed with chronic transplant nephropathy grade 2 (N = 2)
and grade 3 (N = 2). In one of these four biopsies, severe hyaline
arteriolar lesions were present, however, despite this the patient
did not show any episode of acute cyclosporine toxicity.
Histological diagnosis
The mean number of glomeruli per biopsy was 10.2 5.6.
There were 7 or more glomeruli in 70 biopsies. Marginal speci-
mens contained 4.2 1.3 glomeruli. Frozen sections were avail-
able in 77 cases.
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Table 1. Clinical characteristics of patients at the time of surgery
according to histological diagnosis
Normal
Borderline
changes CTN
CTN and
borderline
changes P
N 41 12 30 11
Age years
Sex male/female
PeakPRA%
41 13
21/20
9±19
41 14
9/3
9±17
39 14
15/15
11±21
49 10
9/2
13±20
NS
NS
NS
LastPRA% 4±15 2±4 5±17 1±4 NS
A+B+DR mismatches 2.7 1.1 2.3 1.1 2.9 1.3 3.0 0.9 NS
Donor age years
CIT hours
29 13
24 7
27 14
26 6
32 14
24 7
35 17
25 4
NS
MS
Treatment ALG/OKT3 21/20 8/4 14/16 6/5 NS
Abbreviations are: CTN, chronic transplant nephropathy; CIT, cold
ischemia time; NS, not significant.
Histological diagnoses were categorized according to the Banif
schema. The diagnostic categories were: normal (N = 41), bor-
derline changes (N = 12), chronic transplant nephropathy (N =
41), and acute rejection (N = 4).
Chronic transplant nephropathy (CTN) was mild (grade I) in 34
cases and moderate (grade II) in 7 cases. In 11 out of 41 patients
diagnosed of CTN, mild tubulitis was present. These biopsies with
CTN and tubulitis were initially analyzed as a separate category
(CTN and borderline changes). Mild vascular hyperplasia was
observed in 4 cases.
Acute rejection was mild (grade I) in 3 cases and moderate
(grade II) in 1 case. The number of biopsies in this diagnostic
category was too low for statistical analysis.
Hyaline arteriolar lesions were observed only in four biopsies.
According to the above-mentioned considerations, four diag-
nostic categories were considered in the first statistical approach:
normal (N = 41), borderline changes (N = 12), CTN (N = 30)
and CTN + borderline changes (N = 11). In these 94 patients,
frozen tissue was available in 75 cases. Characteristics of patients
at the time of surgery are summarized in Table 1.
Interstitial volume fraction and interstitial infiltrating cells
Cortical interstitial volume fraction (Vvint/cortex) and number
of interstitial infiltrating leukocytes were quantified in order to
evaluate its relationship to the four histological categories studied
(Tablc 2). Vvint/cortex was increased in patients displaying CTN
while the number of CD45-positive interstitial infiltrating cells was
higher in the CTN + borderline changes group, but this difference
did not reach statistical significance.
Clinical variables and diagnostic categories
Characteristics of patients after surgery according to the four
histological categories are summarized in Table 3. The incidence
of acute rejection before biopsy was lower in patients with normal
histology or borderline changes than in patients with CTN plus or
minus borderline changes. Proteinuria was slightly increased in
patients with CTN associated with borderline changes than in the
other groups. Serum creatinine at the time of biopsy and serum
creatinine at the first year of follow-up was higher in patients
displaying CTN. For this reason, and in order to increase the
Table 2. Cortical interstitial volume fracction (Vvint/cortex) and
number of interstitial infiltrating CD4S positive cells (leukocytes) in
different diagnostic categories
Borderline
CTN +
borderline
Normal changes CTN changes P
N 41 12 30 11
Vvint/cortex % 14.3 4.1 14.1 3.7 18.1 6.2 20.1 0.0003
N 34 9 22 10
CD45 cells/mm2 493 453 511 293 481 399 840 189 NS
Abbreviation CTN is chronic transplant nephropathy.
P < 0.05 versus normal biopsies
5P < 0.05 versus borderline biopsies
number of cases to further analyze data, biopsies were grouped as
the presence or abscence of chronic transplant nephropathy.
In this second analysis, the following variables were significantly
higher in patients with CTN: the incidence of acute rejection,
serum creatinine either at the time of biopsy, at one and two years
of follow-up, as well as the mean cyclosporine level (Table 4). To
study the independent predictors of CTN, a logistic-regression
analysis was performed. The following predictive variables were
considered: recipient's age and sex, donor age, body wt, post-
transplant acute tubular necrosis, mean CsA level and acute
rejection. Only acute rejection (P = 0.015, odds ratio: 17.4, 95%
confidence interval 1.7 to 179) and mean CsA level (P = 0.03,
odds ratio: 1.01, 95% confidence interval 1.005 to 1.2) were
independent predictors of CTN.
Histological damage in biopsies with CTN according to the
presence or absence of an episode of acute rejection before biopsy
Since the incidence of CTN was higher in patients treated for an
episode of acute rejection before the biopsy, we further compared
biopsies with CTN in patients with (N = 10) or without (N = 31)
a previous episode of acute rejection. Banif scores for acute
lesions (glomerulitis, interstitial mononuclear cell infiltration,
tubulitis and intimal arteritis) and the number of CD45 positive
cells/mm2 of cortical interstitium were not different in these two
groups of biopsies (data not shown), but patients who were
treated for an episode of acute rejection before protocol biopsy
had an increased Vvint/cortex (22.3 5.5% vs. 17.4 5.4%, P =
0.017).
Graft survival according to the presence or absence of CTN
The number of grafts lost during follow-up was 8 of 41(19.5%)
in patients displaying CTN and 3 of 53 (5.6%) in patients without
CTN in the protocol biopsy. Actuarial graft survival (Fig. 1) was
significantly lower in patients with CTN (P = 0.024).
Since the presence of an episode of acute rejection before
protocol biopsy, cyclosporine exposure and serum creatinine at
the time of biopsy were associated with the presence of CTN, the
Cox's proportional hazard model was employed to analyze the
influence of these four factors on graft survival.
Only serum creatinine (P = 0.014; hazard rate 1.026, 95%
confidence interval 1,005 to 1.047) and presence or absence of
CTN (P = 0.03; hazard rate 5.98, 95% confidence interval 1.15 to
31.25) were independent predictors of graft loss.
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Table 3. Clinical characteristics of patients during follow-up according to histological diagnosis
Normal
Borderline
changes CTN
CTN and
borderline
changes P
N 41 12 30 11
ATN yes/no 5/36 4/8 8/22 1/10 NS
Acute rejection yes/no 0/41 2/10 7/23 3/8 0.01
Time of biopsy days 68 39 51 27 80 43 59 32 NS
Body weight kg
Proteinuria g/24 hr
61 9
0.31 0.19
61 15
0.39 0.17
63 13
0.27 0.13
63 10
0.51 0.2Y°'
NS
0.0024
Scr at the time of biopsy 120 31 142 40 138 32' 161 37k' 0.003
Scr at 1 year of follow-up 118 24 129 34 146 41 150 3T 0.0018
Scr at 2 years of follow-up 133 54 145 54 171 111 181 87 NS
Mean CsA dose mg/kg/day 7.8 1.6 8.3 1.3 7.7 2.0 8.0 1.5 NS
Mean CsA levels ng/ml 211 61 222 57 240 79 248 62 NS
Mean follow-up months 58 17 61 16 51 18 57 16 NS
Graft loss yes/no 2/39 1/11 5/25 3/8 NS
Abbreviations are: Sr, serum creatinine (j.mol/1iter); ATN, acute tubular necrosis; CsA, cyclosporine.
P < 0.05 versus normal biopsies
b P < 0.05 versus CTN
N
No CTN CTN P
53 41
Scr at the time of biopsy 125 35 145 35 0.008
Sçr at 1 year of follow-up 121 26 148 40 0.0001
Scr at 2 years of follow-up 136 54 174 105 0.024
AR yes/no 2/51 10/31 0.003
Mean CsA levels ng/ml 214 59 242 74 0.049
Abbreviations are: CTN, chronic transplant nephropathy; Se,, serum
creatinine (mol/liter); AR, clinical episode of acute rejection before
performing the protocol biopsy; CsA, cyclosporine.
25 31 37 43 49 56 62 68 74 80
Time, months
Histological diagnosis of acute rejection and graft outcome
None of the four patients who showed histological signs of
acute rejection in the protocol biopsy had a previous episode of
acute rejection, all of them mantained a functioning graft at 61
11 months (range 58 to 75), and their last serum creatinine was
161 26 jtmol/liter (range 143 to 199).
Discussion
The principal findings of our study are that: (a) about 42% of
biopsies performed in stable grafts early after transplantation
displayed CTN according to the Banif diagnostic criteria; (b)
acute rejection before performing the protocol biopsy and cyclo-
sporine exposure were independent predictors of CTN; and (c)
CTN was an independent predictor of graft survival.
The Banif schema [6, 7] has contributed to international
uniformity in the evaluation of renal allograft biopsies, but there
is still scanty information on the utility of this classification system
in clinical practice, especially when it is applied to the evaluation
of stable grafts [11, 121. Renal function is not always included as
a defining condition for stable grafts [Ii, 181, despite the facts that
it is well known that serum creatinine and proteinuria are
powerful predictors of graft outcome [19, 20], and both parame-
ters correlate with the severity of acute and chronic renal lesions
Fig. 1. Actuarial graft survival in patients with chronic transplant nephrop-
athy (dashed line) and in patients without CTN (solid line). P = 0.024.
[21, 22]. In the present study, only patients with a serum creatinine
level of less than 200 JLmol/liter and a proteinuria of less than 1
g/24 hours were included. We used relatively restrictive criteria to
define the graft's stability in an attempt to avoid an overestimation
of the predictive value of protocol biopsies.
The incidence of chronic renal lesions was to a certain extent
higher than expected if the early timing of protocol biopsies is
taken into consideration, hut the morphometric study confirmed
that Vvint/cortex was significantly increased in patients diagnosed
of CTN, although in the majority of these biopsies chronic lesions
were graded as mild. Isoniemi et al [111 reported that about 2/3 of
stable grafts displayed chronic lesions at two years of follow up. In
their study, chronic renal lesions were more severe, which is not
surprising as protocol biopsies were performed later. By contrast,
in sequential biopsies performed in stable grafts during the first
year after transplantation, Rush et a! [12, 23] reported a higher
incidence of the histological diagnosis of acute rejection and a
lower incidence of CTN. For example, at six months of follow up,
28% of their biopsies displayed acute rejection and 25% displayed
Table 4. Clinical characteristics of patients according to histological
diagnosis
(I)
q)
E
(.)
100
80
60
40
20
0
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CTN. Characteristics of patients in their studies differed in some
aspects when compared to our study. They performed the proto-
col biopsy regardless of renal function and the immunosuppres-
sion employed was different. They used a triple regime with
cyclosporine, azathioprine and steroids, while we employed anti-
lymphocytic antibodies as the induction therapy in addition to
cyclosporine and prednisone. In the present work, as well as in the
previously mentioned studies [11, 12, 18, 231, marginal specimens
(biopsies containing less than 7 glomeruli) were included. Evalu-
ation of marginal specimens implies the risk of underestimating
the severity of a given lesion due to its irregular distribution in the
whole kidney [6]. For this reason, we cannot rule out the
possibility that we might have underscored the severity of acute
lesions.
We observed mild tubulitis not only in biopsies with otherwise
normal histology, but also in about 25% of cases with CTN. This
is in agreement with the results of previous studies that reported
that a substantial number of stable grafts display mild tubulitis [6,
10, 231, and confirms that this lesion is also frequently observed in
biopsies with CTN [24]. In our study, the clinical evolution of
patients with normal histology was not different from patients who
displayed borderline changes. Similarly, there were no differences
in the clinical evolution of patients who showed CTN either with
or without tubulitis. This result confirms previous observations
suggesting that the presence of mild tubulitis is not a determinant
factor in graft outcome [6].
Acute rejection is an important predictor of late graft failure
[25—27], although the effect of mild episodes of acute rejection on
graft survival remains a matter of discussion [28]. We observed a
strong association between the diagnosis of CTN and the presence
of a successfully treated episode of acute rejection before per-
forming the protocol biopsy. It has been proposed that patients
who have suffered from an episode of acute rejection may remain
immunologically active [29—32]. In the present study, when only
patients displaying CTN were considered and grouped according
to the presence or absence of acute rejection before biopsy, we did
not observe any difference in the degree of acute lesions or in the
number of CD45-positive interstitial infiltrating cells. Therefore,
our data do not support the hypothesis that the persistence of a
slow active inflammation is responsible for the progression of
chronic renal allograft damage. Alternatively, acute rejection may
be responsible for the induction of irreversible renal lesions that
could trigger hyperfiltration mediated damage [33—37]. Anyway,
our observation indicates that even episodes of rejection with a
good response to antirejection therapy can produce chronic renal
damage.
It is well established that cyclosporine induces interstitial
fibrosis [38, 39]. We observed that cyclosporine exposure was
higher in patients displaying CTN, despite the cyclosporine dose
being similar in both groups. This result suggests that the fibro-
genie effect of cyclosporine appears early after transplantation
and that cyclosporine can contribute to the development of CTN.
It has been shown that a triple regime with cyclosporine, azathio-
prine and prednisone decreases the severity of chronic lesions in
protocol biopsies performed late after transplantation [111. In the
present study, we used antilymphocytic antibodies as the induc-
tion therapy in addition to cyclosporine and prednisone as the
maintenance therapy. It is not clear whether the use of a double
maintenance regime in our patients may have contributed to the
early appearance of chronic lesions either due to a poorer control
of the alloimmune response or to the maintenance of higher
cyclosporine levels. The relatively low incidence of acute rejection
observed in our group of patients [131 argues against the possi-
bility that they received inadequate immunosuppression.
It has been shown that donor age is a determinant factor of
graft outcome [40, 41] and that it is also associated with the
incidence of chronic renal lesions in protocol biopsies performed
at different times of follow-up [11, 18]. The incidence of post-
transplant acute tubular necrosis is also a determinant factor of
graft survival [421. Despite the donor age and incidence of
post-transplant acute tubular necrosis being higher in patients
displaying CTN in the present study, these differences did not
reach statistical significance. Other risk factors for late graft
failure, such as degree of histocompatibility [43] and cold ischemia
time [44], were similar in patients with and without CTN. In the
studied set of patients, acute rejection and cyclosporine exposure
were independent predictors of CTN.
The presence of CTN was associated with a poorer graft
survival. This result is in agreement with Isoniemi et al [11, 45]
and Dimény et al [18], who have recently pointed out the
importance of chronic renal lesions in protocol biopsies with
regard to graft outcome. Since we observed that serum creatinine,
cyclosporine exposure and the incidence of acute rejection were
higher in patients with CTN, we further studied whether any of
these factors contributed to the prediction of graft survival. In the
studied set of patients, the presence of CTN and serum creatinine
were independent predictors of graft failure. However, graft
survival was not influenced by the presence of acute rejection or
cyclosporine exposure, suggesting that other factors may have
played an important role as a cause of graft loss. Obviously, in the
present work the sample size is not large enough to expect that
any factor associated with graft survival in a broad series of
patients can be identified [421. Taking into account this limitation,
we believe that the most reasonable interpretation of our findings
is that CTN observed in early protocol biopsies is the result of
many different confluent immunological and non-immunological
insults, but the predictive value of CTN on graft survival is
probably not dependent on the mechanism of renal injury.
We observed that CTN and serum creatinine were independent
predictors of graft survival. In patients with CTN and an increased
serum creatinine, the risk for late graft failure was the highest. If
we accept that CTN and serum creatinine roughly reflect the
balance between renal supply and metabolic demand [34, 46], it
seems reasonable to speculate that hyperfiltration mediated dam-
age may play an important role in the progression of renal
scarring in this group of patients [33—37].
In summary, we show that the presence of CTN in protocol
biopsies performed early after transplantation in patients with
well functioning grafts provides relevant information to detect
patients at risk of losing their graft due to chronic transplant
nephropathy. The predictive value of protocol biopsies is inde-
pendent of renal functional impairment, at least when patients
with a serum creatinine lower than 200 j.rmol/liter are considered.
This observation may have important implications on the design
of secondary intervention trials aimed to modify the natural
history of chronic transplant nephropathy [47].
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